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DUX4-induced myoblast toxicity
Darko Bosnakovski1,2,4†, Si Ho Choi1,2†, Jessica M Strasser3, Erik A Toso1,2, Michael A Walters3 and Michael Kyba1,2*Abstract
Background: Facioscapulohumeral muscular dystrophy (FSHD) is caused by epigenetic alterations at the D4Z4
macrosatellite repeat locus on chromosome 4, resulting in inappropriate expression of the DUX4 protein. The DUX4
protein is therefore the primary molecular target for therapeutic intervention.
Methods: We have developed a high-throughput screen based on the toxicity of DUX4 when overexpressed in C2C12
myoblasts, and identified inhibitors of DUX4-induced toxicity from within a diverse set of 44,000 small, drug-like
molecules. A total of 1,280 hits were then subjected to secondary screening for activity against DUX4 expressed by
3T3 fibroblasts, for absence of activity against the tet-on system used to conditionally express DUX4, and for potential
effects on cellular proliferation rate.
Results: This allowed us to define a panel of 52 compounds to use as probes to identify essential pathways of DUX4
activity. We tested these compounds for their ability to protect wild-type cells from other types of cell death-inducing
insults. Remarkably, we found that 60% of the DUX4 toxicity inhibitors that we identified also protected cells from
tert-butyl hydrogen peroxide, an oxidative stress-inducing compound. Compounds did not protect against death
induced by caspase activation, DNA damage, protein misfolding, or ER stress. Encouragingly, many of these compounds
are also protective against DUX4 expression in human cells.
Conclusion: These data suggest that oxidative stress is a dominant pathway through which DUX4-provoked toxicity is
mediated in this system, and we speculate that enhancing the oxidative stress response pathway might be clinically
beneficial in FSHD.
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Facioscapulohumeral muscular dystrophy (FSHD) is one
of the most common degenerative myopathies. It is caused
by epigenetic alterations within D4Z4, the macrosatellite
repeat at the end of the long arm of chromosome 4 [1-4],
which arise due to contractions in repeat number [5,6] or
second site mutation of regulators of D4Z4 [7]. FSHD
only arises on a specific ‘pathogenic’ allele of chromosome
4, termed 4qA161 [8,9], the key feature of which is the
presence of a polyadenylation signal [10,11]. This indicates
that an mRNA transcript produced from D4Z4 must be* Correspondence: kyba@umn.edu
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article, unless otherwise stated.polyadenylated to cause disease. The D4Z4 transcript
encodes the DUX4 protein, a double-homeodomain pre-
sumptive transcription factor [12] which kills myoblasts
and other cells when expressed at high levels [13,14].
DUX4 and homologues of DUX4 also have effects when
expressed in myoblasts at low, non-toxic levels: MyoD
expression is lost and cells lose the ability to differentiate
into myotubes [13,15,16]. Because of these pathological
activities, DUX4 is the key molecular target in the devel-
opment of a pharmacological treatment for FSHD.
We have previously developed a cell line in which DUX4
can be induced to various levels of expression with doxy-
cycline (dox) [13]. Here, we use the cell death phenotype
as a screening tool to identify compounds from within a
diverse chemical library that interfere with DUX4. Because
the phenotype requires both activity of the DUX4 protein
and transmission of a signal through one or more cellntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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identify both compounds that interfere directly with the
activity of the DUX4 protein, as well as compounds that
interfere with essential DUX4 downstream pathways lead-
ing to cell death. Since these pathways are not well under-
stood, such compounds could serve as useful probes into
the molecular mechanism by which DUX4 causes cell
death.
Methods
Composition of the library
We screened a 44,000-compound subset of the UT
Southwestern chemical library. Contained within this li-
brary are sub-libraries created by Chemical Diversity (San
Diego, CA, USA), Chembridge (San Diego, CA, USA), and
ComGenex (Budapest, Hungary). The library also contains
smaller chemical collections, notably the Prestwick library
of 1,100 off-patent FDA-approved compounds.
Cell culture
C2C12 cells and the inducible C2C12 cell lines (iC2C12-
DUX4 and iC2C12-Luc) were cultured in proliferation
medium comprising high glucose Dulbecco’s Modified
Eagle Media (DMEM) with L-glutamine and sodium
pyruvate (Gibco), penicillin and streptomycin (P/S,
Gibco), and 20% fetal bovine serum (FBS, Atlanta Bio-
logicals) at 37°C in 5% O2/5% CO2. The i3T3-DUX4 cell
line was cultured in DMEM, P/S, and 10% FBS.
Luciferase assay
iC2C12-luc cells were plated in 384 well plates at 1,000
cells per well. The following day the luciferase was induced
with 500 ng/mL dox. Luminescence was detected by the
Bright-Glo™ Luciferase Assay System (Promega, Maddison,
WI, USA).
High-throughput screen (HTS)
A single cell subclone of iC2C12-DUX4 cells was expanded
and frozen into 80 vials for screening. A large frozen stock
of the cells at the same growth stage was necessary to
minimize variation in cell viability. iC2C12-DUX4 cells
were plated in 384-well dishes at a density of 1,000 cells
per well. One day after plating, compounds were added at
a concentration of 5 μM (diluted in 1% DMSO) followed
by doxycycline at 500 ng/mL. The ATPlite assay (Perkin
Elmer, Waltham, MA, USA) measuring cell viability was
performed 24 h later according to the manufacturer’s
specifications.
Cell death inhibition assays
C2C12 cells were seeded in 25 μL of medium at 625
cells/well in 384 well plates using a Biomek FX robot
(Beckman, Indianapolis, IN, USA). The cells were allowed
to attach for 24 h before adding cell death inducingreagents: Ionomycin (12.5 μM; Cayman, Ann Arbor, MI,
USA), Staurosporine (0.0125 μM; Cayman), tert-butyl-
hydroperoxide (tBHP; 25 μM; Sigma), ABT-263 (12.5 μM;
Selleckchem, Houston, TX, USA), Etoposide (12.5 μM;
Cayman), and Tunicamycin (2.5 μM; Cayman) using an
ECH 550 robot (LabCyte, Sunnyvale, CA, USA). The plates
were then incubated for 24 h and cell viability was
measured using the CellTiter-Glo luminescent assay based
on quantitation of ATP (Promega, Maddison, WI, USA).
Briefly, the plates were equilibrated at room temperature
and media was removed. CellTiter-Glo reagent diluted (1:1)
in PBS was added and the plates were read in the Analyst
AD 96/384 plate reader (LJL Biosystem, Sunnyvale, CA,
USA).
Dose response analyses
For dose response analysis against DUX4, iC2C12-DUX4
cells were treated with compounds at different doses (7.44
μM, 2.47 μM, 0.81 μM, 0.27 μM, 0.09 μM, 0.03 μM, 0.01
μM) followed by dox at 250 ng/mL. For dose response
against tBHP, C2C12 cells were treated with compounds
at different dose (7.44 μM, 2.47 μM, 0.81 μM, 0.27 μM,
0.09 μM, 0.03 μM, 0.01 μM) followed by tert-butyl-
hydroperoxide (tBHP; 25 μM). The plates were then in-
cubated for 24 h and cell viability was measured using
CellTiter-Glo.
DUX4 transfection in 293 T cells
A total of 293T cells were plated in 96 well plates and
transfected with 200 ng of pClneo-DUX4 plasmids using
TransIT-LT1 transfection reagent (Mirus). Cells were
treated with compounds 6 h after transfection and cell
viability measured using CellTiter-Glo luminescent assay
24 h after compound treatment.
Results
Development of the primary screen
Dox-induced DUX4 expression provoked multiple changes,
both obvious and subtle, to C2C12 myoblasts, resulting in
cell death above a certain threshold, with death occurring
more rapidly at higher concentrations of dox. Above 125
ng/mL dox, induction caused cell death within 24 h. Toxic
effects can be observed after 6-8 h of induction, and be-
come more prominent with time. At 36 h post induction
a majority of the cells (>95%) are dead and have lifted
from the plate (Figure 1A) and the few cells still attached
exhibit severe morphological abnormalities and are not
able to proliferate. We used an assay based on colorimet-
ric detection of ATP levels in the cells to quantify viability
after DUX4 expression, and optimized cell number, dox
concentration, and time of exposure, to develop a robust
high-throughput screening assay with a Z-factor value of
0.74 (n = 8) (Figure 1B).
Figure 1 Development of the primary assay. (A) Cell death of iC2C12-DUX4 cells 36 h after addition of 500 ng/mL doxycycline. (B)
Optimization of cell number and dox concentration. The clearest difference between viability of control and DUX4-induced cells was seen at
1,000 cells per well with 500 ng/mL dox. n = 6. Error bars represent SEM.
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Using this system, we performed an initial test screen of
1,120 FDA-approved off-patent compounds (Prestwick
Chemical, France). This screen identified eight compounds,
of which several were classified as antimitotics (Figure 2A).
Since the screen was based on an indirect assay for live
cells, an antimitotic activity seemed counterintuitive. We
therefore considered the possibility that DUX4 kills
rapidly proliferating cells more effectively than slowly
proliferating or non-mitotic cells. To test this, we exposed
C2C12 cells to different concentrations of serum, which
resulted in different rates of growth, and exposed these
cells to different concentrations of dox. We found that
the IC50 of dox was not changed significantly when
cells were growing more slowly (Figure 2B), however the
extent of cell killing was less complete at 24 h when cells
were growing more slowly. This indicated that antimitotic
compounds would be a class of false positives from this
screen, suggesting the importance of secondary screening
for effects on cell proliferation.
HTS on a large synthetic library
We then applied the high throughput screen to an add-
itional 43,000 compounds created specifically for pharma-
cological screening using automated design algorithms that
exclude structures that are likely to be reactive, precipitate
easily or be insoluble, and that comprise structures that aresmall and synthetically accessible (Figure 3A). We identified
a total of 1,280 compounds that showed a difference in via-
bility approximately 3 standard deviations above the mean
control value when added to the culture medium at 5 μM,
and cherry-picked these for secondary screening. Above 3
standard deviations, random chance predicts that approxi-
mately 1% of inactive compounds will be selected, therefore
our first secondary assay was to retest each compound (at 3
different concentrations 1.67, 5, and 15 μM; Figure 3B).
Slightly under half of the cherry-picked compounds showed
activity when retested at least one of these concentrations.
Secondary phenotypic screens
We then tested each compound in a number of secondary
screens designed to eliminate different classes of false posi-
tives. We first tested for effects on C2C12 cell proliferation
using WT unmodified C2C12 cells. Approximately 34
compounds inhibited proliferation when applied at the
dose used in the primary screen (Figure 4A). We also
eliminated 44 compounds that caused elevated scores
on the ATP assay with WT C2C12 cells (Figure 4A).
We anticipated that certain compounds might protect
cells by interfering with the dox-inducible system, and
thereby prevent DUX4 from being expressed when cells
were treated with dox. To identify such compounds, we
tested each compound in C2C12 cells modified to ex-
press luciferase from the identical genomic locus in
Figure 2 Compounds from the Prestwick library. (A) Prestwick compounds identified in the screen. Boxes indicate compounds with antimitotic
activity. (B) Growth rate-dependence of toxicity. Left: 24-h toxicity of DUX4 against cells growing in media of different serum concentrations. Right:
Toxicity of DUX4 expressed as relative viability at 500 ng/mL dox compared to no dox. Note that as cells grow more slowly, the relative difference in
viability between control and DUX4-induced cells diminishes.
Bosnakovski et al. Skeletal Muscle 2014, 4:4 Page 4 of 11
http://www.skeletalmusclejournal.com/content/4/1/4which DUX4 was expressed [13]. This identified 52
compounds that inhibited luciferase expression after 24 h
of dox treatment, which therefore act by inhibiting the
dox-inducible system (Figure 4B).
To eliminate compounds that acted on cell-type specific
pathways, we then screened all compounds at three con-
centrations (1.67, 5, and 15 μM) on 3T3 cells modified to
express DUX4 in response to dox. Initial cell number, in-
duction time, and concentration of dox were optimized for
the new cell line. Slightly over 60% of compounds identifiedas active in protecting C2C12 cells from DUX4 also
protected 3T3 cells from DUX4 to a level of 3 standard
deviations above the untreated control in at least one
concentration (Figure 4C).
Identification of chemical series and purchase of
selected compounds
After eliminating those compounds that did not repeat in
the primary assay and those that failed various secondary
assays, we were left with 183 compounds. The pattern of
Figure 3 Primary screen of 44,000 compounds and confirmation of activity. (A) Example screening results for the first approximately 10 K
compounds. Viability of cells exposed to 500 ng/mL dox and 5 μM compound is indicated on the y-axis, normalized to control wells, not treated
with doxycycline. Red circles indicate viability scores ≥3 SD above the mean viability. (B) Retesting of compounds at 1.67 μM, 5 μM, and 15 μM.
(C) Schematic of workflow. Primary HTS identified rare ‘hits’, which were then collected in very small volumes into cherry-picked plates. These
were then used for secondary screens. Using data from the secondary screens, individual compounds are identified for deeper study.
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the original hit set, we identified 39 chemical series. Those
compounds that passed through all of the secondary
screens represented 26 chemical series, comprising 120
compounds and 63 singlet compounds with no structur-
ally similar compound within the cherry-picked set. These
chemical series are outlined in Figure 5. Interestingly, one
of the eight Prestwick compounds, ethoxyquin, an antioxi-
dant, falls into series 2. We selected 54 compounds to
purchase, prioritizing those within chemical series, thosewith desirable medicinal chemical properties or otherwise
interesting structures. We identified a number of com-
pounds that had structures known to be associated with
interference with multiple assays (pan-assay interfering
compounds, PAINS [17]) and we specifically avoided these.
We verified the identity of each purchased compound by
mass spectrometry, and tested each of these in the primary
DUX4-mediated cell death assay over a range of con-
centrations. With the exception of two compounds that
failed identity/purity, all compounds demonstrated activity
Figure 4 Secondary screens. (A) Effects of compounds on cell proliferation. (B) Effects of compounds on a dox-inducible luciferase transgene.
Compounds inhibiting luciferase expression are predicted to also inhibit DUX4 expression and thus give a false positive increase in viability.
(C) Protection of an independent cell line (i3T3-DUX4) from cell death induced by DUX4. (D) Screening tree. At left is the graphed the maximum
viability at any dose of each compound in the repeat of the primary screen. Green circles indicate compounds considered to have passed this
screen (that is, repeated the primary screen by protecting cells against DUX4), and the activity of these compounds is indicated in the following
panel. The middle panel shows the activity of the selected compounds on the first two secondary screens: effect on growth rate shown on the
y-axis, and inhibition of luciferase (minimum luciferase expression at any concentration of compound) on the x-axis. All compounds are plotted,
those with activity in the previous assay are shown as green circles, those that failed the previous assay are shown as gray circles. The box indicates
cutoffs set for growth rate and dox-inducible luciferase assays. The third panel shows the activity of selected compounds (that is, those
within the box, which did not alter growth rate or affect dox-inducible luciferase expression levels) against DUX4-expressing 3 T3 cells on
the y-axis vs. the repeat of the primary assay (same data as the far left panel) on the x-axis. Compounds indicated in green protect against
DUX4 independent of cell type.
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Additional file 1: Table S1). Interestingly, four of the top
eight compounds (in terms of maximum viability at any
dose) were from chemical series 2.Activity of the panel of compounds against other cell
death insults
Besides compounds that interfere directly with the activity
of a protein, a cell-based screen can identify compounds
Figure 5 Chemical series identified in the set of specifically active compounds. (A) Number of compounds in each chemical series.
(B) Structures of selected compounds from the top six chemical series. The core that defines the chemical series is shown in blue.
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of the protein, or downstream, with pathways that are
activated by the protein. We reasoned that because the
primary screen was based on cell death, it might have
recovered mainly antiapoptotic compounds. We therefore
tested the panel of 52 selected compounds for protection
against a variety of cell-death inducing stimuli, beginning
with ABT-263 a compound that induces apoptosis directly
by inhibiting Bcl2 [18]. No compounds were able to
interfere with apoptosis induced by interfering directly
with Bcl2 (Figure 6B). We then tested various cell
death-inducing agents that act by stimulating various
stress pathways. No compounds were protective against
the broad kinase inhibitor, Staurosporine (Figure 6C);
the DNA double-strand break-inducing agent, Etoposide
(Figure 6D); the Ca-permeablizer, Ionomycin (Figure 6E);
or a ER stress inducer, Tunicamycin (Figure 6G). Remark-
ably however, two-thirds of our hits showed significant
protection from tBHP (tert-butyl hydrogen peroxide), an
oxidative stress-inducing agent (Figure 6F). Some of these
compounds are predicted to be antioxidants based on
chemistry (compounds 47 and 52), or similarity to known
antioxidants (ethoxyquin, series 2), while the majority
lack obvious reducing activity. To further evaluate theanti-oxidative stress activity of these compounds, we tested
them against an independent cell type (3 T3 cells) ex-
posed to tBHP (Figure 6H). Compounds that protected
from tBHP tended to do so equally well in both cell types
(Figure 6I). To better characterize the tBHP protective
activity of these compounds, we tested each compound
over a range of doses and ordered their activity (Additional
file 2: Table S2).
Activity of the panel of compounds in DUX4-expressing
human cells
Finally, to determine whether any of these compounds
showed activity in human cells expressing DUX4, we
tested the panel of compounds on DUX4-expressing
293T cells. Of the 52 compounds, 32 compounds showed
a significant improvement in viability of 293T cells express-
ing DUX4 (Figure 6J).
Discussion
FSHD is one of the most common myopathies, with an
estimated incidence of 1/20,000 at birth [19,20]. The
disease is usually noticed in the teen years, is typically
slowly progressive, and because heart and diaphragm are
spared, affected individuals live relatively normal lifespans.
Figure 6 (See legend on next page.)
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Figure 6 Activity of repurchased compounds on cell death induced by DUX4 or other cytotoxic pathways. (A) Viability of DUX4-expressing
C2C12 cells exposed to various concentrations of compounds, from 0.01 μM to 7.44 μM. Compounds are arranged in order of greatest viability at any
concentration. Four Prestwich compounds are also shown: α-tocopherol, vitamin K2, ethoxyquin, and ethopropazine HCl. B-G: Viability of C2C12 cells
exposed to various cell death-inducing compounds in the presence of 5 μM compounds 1 to 52 (the active compounds of the 54 that were
purchased). The Y axis represents viability (ATP content). The first point in each series represents untreated cells, the second represents cells
treated with toxic agent alone, and the remaining points represent cells treated with toxic agent plus inhibitory compounds, in order from 1 to
52 (n = 3), error bars = SEM. The dashed red line represents 3 standard deviations above the control sample without compound. (B) Protection from
ABT-263. (C) Protection from Staurosporine. (D) Protection from Etoposide. (E) Protection from Ionomycin. (F) Protection from tBHP. (G) Protection
from Tunicamycin. (H) Viability of 3T3 cells exposed to tBHP in the presence of compounds 1 to 52. (I) Protection from tBHP in C2C12 cells vs. 3T3 cells.
R = Spearman’s correlation coefficient. The strong correlation indicates that compounds tend to protect equally well in both cell types. (J) Activity of
52 repurchased compounds on cell death induced by DUX4 in 293 T cells. Viability of 293T cells transfected with vector control (EV), DUX4 plus carrier
(DMSO) alone, or DUX4 and treated with of 5 μM compounds 1 to 52 (n = 6). The Y axis represents improvement in viability over DUX4 transfection
alone. Red dots represent compounds that gave a statistically significant (P <0.05) improvement in viability over DUX4 treatment with carrier alone.
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order as the more common but lethal Duchenne muscular
dystrophy, and that FSHD patients face a lifetime of dealing
with the devastating effects of this muscular dystrophy.
There is currently no treatment for FSHD, thus there is
an acute and significant need for new medicines in this
area. Research on pharmacological inhibitors in FSHD
has lagged badly behind advances that have been made over
the past decade for many less prevalent genetic diseases.
This can be attributed to the genetic complexity of FSHD:
the fact that it is not a simple loss or gain of function within
a classical gene has led to a variety of poorly-supported,
conflicting models, and with the lack of an agreed upon
molecular target, a lack of interest in drug development.
Although the mechanism by which muscle degeneration
occurs is still not well understood, the recent pinpointing
of stabilized mRNA encoding DUX4 as essential for FSHD
[11], now provides a molecular target in this disease.
Because the effects of DUX4 on C2C12 myoblasts are
rapid and easily quantified (cells die in the presence of
DUX4), this system enables a highly sensitive cell-based
assay. The iC2C12-DUX4 cell line that we have used for
these studies is clonal, and the level of DUX4 can be
titrated by varying the dose of the inducer, doxycycline.
These features provide the system with excellent reprodu-
cibility, and therefore allowed us to identify and validate a
large set of compounds that protect myoblast cells from
the cytotoxic effects of DUX4. The main false positives
that we expected were inhibitors of the Tet-on system,
and these were effectively identified by using a related cell
line, in which luciferase was introduced into the identical
genomic locus, regulated by dox in the same manner as
DUX4. Although we identified a subset of Tet-on/luciferase
inhibitors within our primary hit set, this was not the
largest class of false positives. Rather, an unexpected class
of compounds inhibiting cell proliferation represented the
largest subset. Using a simple serum-titration experiment
to test DUX4 toxicity in cells proliferating at different rates,
we discovered that the cell-based screen we used gave the
greatest differential readout when cells were proliferatingmost rapidly. We assume that this is due in part to the
compounding effect of cell proliferation during the 24 h of
exposure to DUX4 in which the screen was performed, and
in part to a greater sensitivity of rapidly dividing cells. The
final secondary screen that we subjected our hit set to was
to test compounds to see whether they also protect 3T3
cells from DUX4. Although FSHD is a disease of muscle, it
is not proven that non-myogenic cells have no role, and
useful inhibitors ought to protect from the effect of DUX4
on as many cell types as possible. However, in view of the
possibility that there may be muscle-specific pathways that
might be able to inhibit DUX4 activity, we carefully evalu-
ated the set of compounds eliminated by this final screen,
and found that 53 of them were within the identified
chemical series, more or less randomly distributed. The
lack of C2C12-specific chemical series argues against the
idea that these compounds act in muscle-specific inhibi-
tory pathways.
This rigorous secondary screening tree reduced our
1,280 compound hit set to 183 compounds, representing
an effective hit rate of 1/240 compounds over the entire
set of 44,000 compounds screened. Within the initial
1,280 hit set, we identified 39 chemical series. In some
series, the majority of members passed all secondary
screens to make it into the 183 compound hit set, while
in others, none or only a small subset passed. At this
point, assignments to chemical series are highly provisional,
and it is likely that many of these series, especially the ones
with 20+ members, are grouping compounds based on a
feature that is not responsible for activity.
From these 183 compounds, 54 compounds were pur-
chased and retested, and all but two showed activity when
tested again in the primary screen. Each of these 52 com-
pounds then, blocks the toxic activity of DUX4 in C2C12
myoblasts. The mechanism of activity of these compounds
is not currently known, and because the cell death pheno-
type against which we screened is likely the product of a
multistep pathway, it is probable that these compounds
can be further segregated into subclasses based on targeting
DUX4 directly, targeting an upstream pathway necessary
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ways responsible for carrying out DUX4-mediated cell
death. To help stratify the compounds we identified into
different subgroups, and to gain insight into which path-
ways were relevant to DUX4-mediated cell death, we
tested each compound for the ability to provide protection
against six different types of cell death-inducing insults.
Remarkably, this identified a large subset of compounds
that acts downstream of DUX4 in the oxidative stress
pathway. In addition, although they protected only mod-
estly compared to the 52 selected compounds, several of
the Prestwick compounds are also annotated as anti-
oxidants. Most of the compounds that we selected lack
obvious reducing activity, suggesting that they protect
from oxidative stress indirectly, probably by stimulating
pathways that promote the cells’ own antioxidant defenses.
The mechanism of action of each compound bears further
study, however given that so many of the protective
compounds also protect against oxidative stress, it seems
likely that oxidative stress is a major downstream effector
pathway of DUX4. Because our library was not directed
against a specific pathway, but was indeed random, the
fact that the majority of protective compounds also pro-
tect against oxidative stress and that no compounds were
simple non-specific inhibitors of apoptosis or other cell
death insults, it seems that oxidative stress is the critical
pathway by which DUX4 is toxic in this system. This is
interesting because markers of oxidative stress have been
observed in FSHD muscle [21]. In addition, expression
profiling in FSHD myoblasts [22] and in cells misexpressing
DUX4 [13] suggests that genes involved in oxidative stress
response are misregulated. In addition, myoblasts from
FSHD patients have been described to be more sensitive to
oxidative stress than control myoblasts [23]. Together, these
data suggest that protecting cells from oxidative stress, per-
haps through one of the inhibitors identified in this study,
might be therapeutically beneficial to FSHD patients.
For approximately one-third of the inhibitors we discov-
ered we were not able to identify a pathway downstream of
DUX4 in which the inhibitor acted. This could mean
that these compounds act on DUX4 itself, or on a path-
way required for its activity, for example activity of a
kinase that phosphorylates DUX4, or against an as-yet
unidentified downstream pathway. Further work will be
necessary to identify how these compounds are protective
against DUX4, and whether they might be suitable for
drug development.
Conclusion
These studies identify inhibitors of DUX4-mediated tox-
icity, and demonstrate that such compounds can be used
as probes of DUX4 pathology. They support a model in
which oxidative stress is an important downstream pathway
in the pathology of FSHD.Additional files
Additional file 1: Table S1. Dose response analyses for the 52 and
Prestwick compounds against DUX4-induced toxicity in iC2C12-DUX4 cells.
Additional file 2: Table S2. Activity of the 52 compounds and 4
Prestwick compounds against tBHP-induced toxicity in C2C12 cells.
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